$STOK
Stoke Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037497 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $3.268M $2.905M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.384M $9.944M $8.325M
YoY Change 7.57% 19.45% 48.66%
% of Gross Profit
Research & Development $21.06M $20.11M $14.36M
YoY Change 33.27% 40.05% 77.04%
% of Gross Profit
Depreciation & Amortization $609.0K $388.0K $254.0K
YoY Change 159.15% 52.76% 10.43%
% of Gross Profit
Operating Expenses $30.44M $30.05M $22.68M
YoY Change 24.13% 32.49% 65.44%
Operating Profit -$27.15M -$22.68M
YoY Change 19.68% 65.44%
Interest Expense $1.479M $995.0K $44.00K
YoY Change 4008.33% 2161.36% 340.0%
% of Operating Profit
Other Income/Expense, Net $42.00K $1.037M $42.00K
YoY Change 0.0% 2369.05% 110.0%
Pretax Income -$25.66M -$26.11M -$22.60M
YoY Change 4.94% 15.55% 65.18%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.66M -$26.11M -$22.60M
YoY Change 4.94% 15.55% 65.13%
Net Earnings / Revenue -785.04% -898.83%
Basic Earnings Per Share -$0.66 -$0.61
Diluted Earnings Per Share -$0.65 -$0.63 -$614.7K
COMMON SHARES
Basic Shares Outstanding 39.43M 39.42M 36.76M
Diluted Shares Outstanding 39.26M 36.71M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $229.6M $251.7M $236.2M
YoY Change 4.45% 6.56% 23.32%
Cash & Equivalents $113.6M $113.4M $149.0M
Short-Term Investments $116.0M $138.3M $87.12M
Other Short-Term Assets $2.955M $12.55M $8.732M
YoY Change -68.14% 43.74% 118.3%
Inventory
Prepaid Expenses $10.93M
Receivables
Other Receivables
Total Short-Term Assets $244.1M $264.6M $244.9M
YoY Change 6.48% 8.03% 25.29%
LONG-TERM ASSETS
Property, Plant & Equipment $6.675M $7.161M $8.269M
YoY Change 61.27% -13.4% 92.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $569.0K $569.0K $569.0K
YoY Change 0.0% 0.0% 184.5%
Total Long-Term Assets $12.00M $13.03M $8.838M
YoY Change 24.36% 47.37% 100.86%
TOTAL ASSETS
Total Short-Term Assets $244.1M $264.6M $244.9M
Total Long-Term Assets $12.00M $13.03M $8.838M
Total Assets $256.1M $277.6M $253.8M
YoY Change 7.2% 9.4% 26.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $766.0K $1.911M $655.0K
YoY Change -67.88% 191.76% -40.45%
Accrued Expenses $15.24M $13.62M $10.90M
YoY Change 7.21% 24.94% 101.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.39M $28.80M $11.88M
YoY Change 83.17% 142.3% 77.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.968M $3.610M $4.374M
YoY Change -24.84% -17.47% 524.86%
Total Long-Term Liabilities $39.82M $44.69M $4.374M
YoY Change 908.46% 921.67% 524.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.39M $28.80M $11.88M
Total Long-Term Liabilities $39.82M $44.69M $4.374M
Total Liabilities $71.22M $73.48M $16.26M
YoY Change 237.72% 351.98% 119.7%
SHAREHOLDERS EQUITY
Retained Earnings -$297.2M -$271.5M
YoY Change 51.54%
Common Stock $4.000K $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $184.8M $204.1M $237.5M
YoY Change
Total Liabilities & Shareholders Equity $256.1M $277.6M $253.8M
YoY Change 7.2% 9.4% 26.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$25.66M -$26.11M -$22.60M
YoY Change 4.94% 15.55% 65.13%
Depreciation, Depletion And Amortization $609.0K $388.0K $254.0K
YoY Change 159.15% 52.76% 10.43%
Cash From Operating Activities -$22.37M -$22.06M -$14.68M
YoY Change 37.61% 50.22% 35.07%
INVESTING ACTIVITIES
Capital Expenditures $409.0K -$2.030M -$273.0K
YoY Change -301.48% 643.59% 1.11%
Acquisitions
YoY Change
Other Investing Activities $22.90M $69.29M -$4.991M
YoY Change 90.83% -1488.38%
Cash From Investing Activities $22.49M $67.26M -$5.264M
YoY Change 90.64% -1377.81% 1849.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.00K 434.0K 408.0K
YoY Change -74.85% 6.37% -39.1%
NET CHANGE
Cash From Operating Activities -22.37M -22.06M -14.68M
Cash From Investing Activities 22.49M 67.26M -5.264M
Cash From Financing Activities 43.00K 434.0K 408.0K
Net Change In Cash 160.0K 45.64M -19.54M
YoY Change -103.73% -333.61% 86.61%
FREE CASH FLOW
Cash From Operating Activities -$22.37M -$22.06M -$14.68M
Capital Expenditures $409.0K -$2.030M -$273.0K
Free Cash Flow -$22.78M -$20.03M -$14.41M
YoY Change 41.9% 38.98% 35.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001623526
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39258358
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36708188
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38358936
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2385000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
182000
CY2022Q3 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14046000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Registrant Name
EntityRegistrantName
Stoke Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Trading Symbol
TradingSymbol
STOK
CY2021Q4 us-gaap Assets Current
AssetsCurrent
229218000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5295000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4939000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7161000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4139000
CY2021Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14754000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12838000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28795000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17139000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41078000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3610000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3949000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
44688000
CY2022Q3 us-gaap Liabilities
Liabilities
73483000
CY2021Q4 us-gaap Liabilities
Liabilities
21088000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36902499
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36902499
us-gaap Revenues
Revenues
9137000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14358000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56777000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38366000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9944000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8325000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29540000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23173000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
30053000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
22683000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1643000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
84000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
125000
us-gaap Operating Expenses
OperatingExpenses
61539000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
86000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22577000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76947000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26538000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39420310
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36759319
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38716615
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36706647
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22597000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
us-gaap Net Income Loss
NetIncomeLoss
-61357000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-427000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1535000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-427000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
20000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1535000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61379000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286078000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2698000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
371000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
175000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21967000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4452000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
161000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
255069000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
239977000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity File Number
EntityFileNumber
001-38938
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39430747
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113396000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144895000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
138259000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
74915000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12551000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9159000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
117000
CY2022Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
395000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
132000
CY2021Q4 us-gaap Assets
Assets
238865000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1911000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
477337000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
414024000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1703000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-168000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271495000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196083000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
204143000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
217777000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
277626000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
238865000
CY2022Q3 us-gaap Revenues
Revenues
2905000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39426440
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39426440
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20109000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
237513000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
264601000
CY2022Q3 us-gaap Assets
Assets
277626000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
326000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3949000
CY2022Q2 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
3099000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
224321000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
us-gaap Operating Expenses
OperatingExpenses
86317000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36675876
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39258358
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36708188
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38358936
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36675876
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27148000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22683000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1037000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1768000
us-gaap Net Income Loss
NetIncomeLoss
-61357000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16793000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22597000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4614000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
334000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
217777000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24649000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4975000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-516000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2022Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
42128000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24652000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6163000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-592000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5926000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-427000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
401000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
204143000
us-gaap Profit Loss
ProfitLoss
-75412000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88223000
us-gaap Profit Loss
ProfitLoss
-61357000
us-gaap Depreciation
Depreciation
937000
us-gaap Depreciation
Depreciation
739000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
-60000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
86000
us-gaap Share Based Compensation
ShareBasedCompensation
17064000
us-gaap Share Based Compensation
ShareBasedCompensation
11764000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
1446000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
870000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3655000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2073000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3729000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-707000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
53916000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9493000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50649000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
206190000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
87226000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3553000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
997000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
141371000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68372000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
570000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
509000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
452000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
605000
stok Proceeds From Controlled Equity Offering Sales Agreement
ProceedsFromControlledEquityOfferingSalesAgreement
45344000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46366000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1113000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31499000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-137759000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145464000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
287513000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113965000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149754000
stok Right Of Use Assets Recognized In Exchange For Operating Leases
RightOfUseAssetsRecognizedInExchangeForOperatingLeases
1802000
stok Right Of Use Assets Recognized In Exchange For Operating Leases
RightOfUseAssetsRecognizedInExchangeForOperatingLeases
5081000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
406000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113396000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149038000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
147000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113965000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
149754000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue in accordance with ASC Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (“ASC 606”). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company entered into a collaboration and licensing agreement with Acadia Pharmaceuticals, Inc. (“Acadia”) which is within the scope of ASC 606 (see Note 7).   In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under this agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for this arrangement, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company’s condensed consolidated balance sheets. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s condensed consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Upfront license fees</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licenses of the Company’s intellectual property granted to Acadia was not determined to be distinct from the other promises or performance obligations identified in the arrangement.  Accordingly, such licenses are therefore combined with other promises in the arrangement. The Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Customer options</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. No such material rights were identified in the arrangement with Acadia.  If such material rights were identified, then the Company would allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized or begin to be recognized as revenue until, at the earliest, the option is exercised. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development services</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company’s collaboration agreement with Acadia includes research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of the Acadia arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.  The development milestones in the Acadia arrangement are not considered probable of achievement at the outset of the arrangement.</p>
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
139962000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1703000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
138259000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
75083000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
168000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
74915000
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4289000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5383000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
629000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
523000
CY2022Q3 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6389000
CY2021Q4 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6801000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2313000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1507000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
426000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
540000
CY2022Q3 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14046000
CY2021Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14754000
CY2018Q3 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
23000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
900000
CY2018Q3 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.03
CY2018Q3 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2018-12-10
CY2018Q4 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
2485
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 stok Number Of Renewal Option To Extend Operating Lease Terms
NumberOfRenewalOptionToExtendOperatingLeaseTerms
1
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2018Q4 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
200000
CY2018Q4 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.025
CY2018Q4 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2019-05-01
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
616000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2532000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2609000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
172000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5929000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
298000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5631000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5295000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2313000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3318000
CY2022Q3 stok Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted
OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
5631000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0469
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
79400
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
54500000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
54500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y8M19D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5926000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4614000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17064000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11764000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26111000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22597000
us-gaap Net Income Loss
NetIncomeLoss
-75412000
us-gaap Net Income Loss
NetIncomeLoss
-61357000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39420310
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36759319
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38716615
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36706647
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
66000000.0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0001564590-22-037497-index-headers.html Edgar Link pending
0001564590-22-037497-index.html Edgar Link pending
0001564590-22-037497.txt Edgar Link pending
0001564590-22-037497-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g2su0hd1o0aa000001.jpg Edgar Link pending
g2su0hd1o0aa000002.jpg Edgar Link pending
g2su0hd1o0aa000003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stok-10q_20220930.htm Edgar Link pending
stok-20220930.xsd Edgar Link pending
stok-ex311_9.htm Edgar Link pending
stok-ex312_8.htm Edgar Link pending
stok-ex321_10.htm Edgar Link pending
stok-ex322_7.htm Edgar Link pending
stok-20220930_def.xml Edgar Link unprocessable
stok-20220930_lab.xml Edgar Link unprocessable
stok-20220930_pre.xml Edgar Link unprocessable
stok-10q_20220930_htm.xml Edgar Link completed
stok-20220930_cal.xml Edgar Link unprocessable